Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.
Trial Details
- NCT ID
- NCT06771544
- Phase
- PHASE2
- Sponsor
- University of California, Irvine
- Status
- RECRUITING
- Cancer Type
- Melanoma
- Interventions
- Pembrolizumab
- Cyclophosphamide
- Locations (sample)
- Orange, California, United States|33.78779,-117.85311
Key Eligibility Criteria
- Age ≥18 years at the time of signing informed consent form (ICF)
- Patients must have unresectable Stage III or Stage IV non-ocular melanoma per American Joint Committee on Cancer 8th Edition Staging Criteria not a…
- Participants must have measurable disease by RECIST v1.1 criteria as assessed by investigator/ radiology. Lesions situated in a previously irradiat…
- Participants must have Eastern Cooperative Group (ECOG) performance status score of 0, 1 or 2 at screening visit.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Melanoma Trials on Trialify →